Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category.
A bipartisan bill has been introduced in the US Congress that will try to block Centers for Medicare and Medicaid Services (CMS) restrictions on Biogen's Alzheimer's therapy Aduhelm being e
In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.
UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as it fights to retain its stock market listing in the US.
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-sell
Biogen and Eisai are riding high on the wave of optimism set in motion by the top-line data drop for Alzheimer's therapy lecanemab – but a number of breakwaters could lie ahead.
Precision medicine is oft spoken about these days, as it is finally addressing the elephant in the room: one size – or, more appropriately, one dose – does not fit all.